Air Force Medical Research and Development

 

To enhance the health, safety, readiness, and performance of Air Force personnel through applied medical research and advanced development executed largely through grants, cooperative agreements, and contracts with civilian educational and research institutions/organizations.

Active 12.810 Department of The Air Force, Department of Defense B - Project Grants Fiscal Year 2018 "Transition of Advanced Trauma, Hemorrhage and Vascular Injury Products." This project provides for the development, design, refinement, evaluation, certification and transition of innovative dual-use technologies that will help revolutionize the delivery and efficacy of acute trauma and resuscitative care to patients suffering life threatening illnesses and injuries. The trauma and resuscitative product line is an especially important focus area for military medicine due to the prevalence and nature of injuries and illnesses that affect DoD personnel in performance of their mission responsibilities.
Fiscal Year 2019 Field Intravenous Expeditionary System – a system to generate Sterile Water for Injection (SWFI) to constitute multiple formulations of intravenous (IV) solutions consisting of ringers lactate, lyophilized human plasma, saline and other sterile fluids and/or biologics and medications Expeditionary Medical Support system (EMEDS) sites. This is being overseen and managed by the prime (Military & Health Research Foundation, MHRF) and executed by the subcontractor (Parker-Hannifin). Endovascular Variable Aortic Control - a clinically viable catheter with integrated solid-state sensors and a blood pressure monitor that will control blood flow in patients with non-compressible truncal hemorrhage in a way that reduces distal ischemia and organ damage below the balloon when compared to current technologies. This project will result in a completed device ready for verification and validation testing in support FDA 510(k) clearance.
Fiscal Year 2021 Field Intravenous Expeditionary System – a system to generate Sterile Water for Injection (SWFI) to constitute multiple formulations of intravenous (IV) solutions consisting of ringers lactate, lyophilized human plasma, saline and other sterile fluids and/or biologics and medications Expeditionary Medical Support system (EMEDS) sites.
Fiscal Year 2023 N/A 10 U.S.C. 2358 Applicants must be an institution/organization. Applications will not be accepted from individuals. Applicants must be an institution/organization. Applications will not be accepted from individuals. Applicants must furnish evidence of legal authorization, financial and managerial capability as well as a certification of compliance with Federal, State, and local environmental laws, ordinances and regulations. Preapplication coordination is required. See funding announcement This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Merit-based competitive procedures are utilized in accordance with notices of funding opportunities, such notices are typically called Program Announcements (PAs) or Broad Agency Announcements (BAAs). Proposals are evaluated by in-house committee and extramural review committees against the evaluation criteria listed in the Broad Agency Announcement (BAA) or Program Announcement (PA). The final stage of evaluation is the establishment of an order of merit in which all competing proposals are ranked on the basis of their respective military relevance and scientific merit evaluations. Award amount will be negotiated with those proposals recommended for funding. Awards depend upon the availability of funds and the priority which the Air Force determines to exist at the time of award. Contact the headquarters or regional location, as appropriate for application deadlines From 120 to 180 days. Not applicable. From 120 to 180 days. Once a grant or cooperative agreement is awarded, any follow-on research proposal is treated as a new request. Follow-on work should allow for the review time noted above. Proposals are selected for funding based on the evaluation criteria listed in the Command's Broad Agency Announcement (BAA) or Program Announcements (PAs). The BAA and PAs can be viewed at the Grants.gov website. Recipients are required to conform to their accepted research protocol and are usually required to submit some form of annual or project report. Project support is limited to research and development aimed at sustaining or enhancing the technology base or understanding a biological- medical process, thereby providing a technological edge in solving complex biological-medical problems and countering future military medical threats. Performance Reports: Periodic Program Performance review in the form of Program Management Reviews on an annual basis as well as In-Progress Reviews that are scheduled on an ad-hoc / as needed basis. Interim performance reports Not applicable. Record keeping requirements are in accordance with the terms and conditions of the award, which will include appropriate provisions related to recipient records that are required by the DoDGARs. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Assistance programs are normally available for work efforts that will be concluded within 3 years (36 months) from the date of award. Payments are made in accordance with the terms and conditions of the award, which will comply with the DoD Grant and Agreement Regulations (DoDGARs). None/Not specified. VENTON LAMONT
SAF/AQC
1060 Air Force Pentagon 4C149
Washington, DC 20330 USA
venton.lamont.2@us.af.mil
Phone: 703-672-1363 http://www.af.mil 97-0130-7-1-833 (Project Grants (Cooperative Agreements or Contracts)) FY 22$0.00; FY 23 est $0.00; FY 24 est $0.00; FY 21$0.00; FY 20$990,000.00; FY 19$627,624.00; FY 18$1,926,460.00; FY 17 FY 15$3,410,625.00; FY 16 est $3,200,000.00; - Not applicable/available. Command's Broad Agency Announcement (BAA) or Program Announcements (PAs) provide program information, applicable regulations, and guidance for submitting applications. The BAA and PAs can be viewed at the Grants.gov website. Fiscal Year 2021 Endovascular Variable Aortic Control - a clinically viable catheter with integrated solid-state sensors and a blood pressure monitor that will control blood flow in patients with non-compressible truncal hemorrhage in a way that reduces distal ischemia and organ damage below the balloon when compared to current technologies. This project will result in a completed device ready for verification and validation testing in support FDA 510(k) clearance.